Not logged in
Share
SaveLipid tail heterogeneity enables organ-selective mRNA delivery for in vivo CRISPR-Cas9 gene editing
Liao, Jing; Zeng, Ling; Zhang, Zixi; Tang, Yingsen; Harmon, Joseph; Liu, Fuguo; Ren, Yupeng; Shen, Qian; Liao, Hangping; Jiang, Meng; Fan, Hui; Cao, Xinxiu; Ye, Zhongfeng; Chen, Jinjin
Share
SaveA Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan-Tissue Antigen-Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy
Zeng, Ling; Shen, Qian; Wei, Lingyu; Jiang, Meng; Liao, Jing; Ren, Yupeng; Zhang, Zixi; Fan, Hui; Cao, Xinxiu; Chen, Jinjin; Ding, Jianxun; Chen, Xuesi
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
SavePancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma
Shen, Qian; Liu, Jia; Zeng, Ling; Ren, Yupeng; Liao, Jing; Chen, Sijie; Tang, Yingsen; Zhang, Zixi; Jiang, Meng; Liao, Hangping; Wang, Lingyun; Xu, Xiaoding; Chen, Jinjin
Share
Save
Share
SaveCircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis
Tang, YC; Yuan, F; Cao, MB; Ren, YP; Li, YX; Yang, GY; Zhong, ZZ; Liang, H; Xiong, ZY; He, ZW; Lin, N; Deng, MH; Yao, ZC
Share
Save
Share
Save
Share
SaveCircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt/β-catenin pathway via the miR-452-5p/ SOX15 axis
Yuan, Feng; Tang, Yongchang; Liang, Hao; Cao, Mingbo; Ren, Yupeng; Li, Yuxuan; Yang, Gaoyuan; Zhong, Zhaozhong; Xiong, Zhiyong; He, Zhiwei; Deng, Meihai; Yao, Zhicheng
Share
Save
Share
Save
Share
Save
Share
Save
Share
SaveEfficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial
Ren, Yupeng; Li, Yuxuan; Cao, Mingbo; Tang, Yongchang; Yuan, Feng; Yang, Gaoyuan; He, Zhiwei; Shi, Zheng; Su, Xiaorui; Yao, Zhicheng; Deng, Meihai
Share
Save